Close Menu

More articles about Business News

The first year's pilot phase aimed to develop an infectious disease digital health and precision medicine platform connecting healthcare facilities to NYSDOH.

he firm will use the proceeds to expand manufacturing capacity for its existing and in-development COVID-19 assays.

The technologies, called non-extensible oligonucleotides and linear DNA assembly, may help the sample prep firm improve existing products.

The firm presented a poster at ASCO suggesting that its StemPrintER platform outperforms Exact Science's Oncotype Dx for predicting breast cancer recurrence.

The company said it is using the technology for synthetic biology, diagnosis of inherited genetic diseases, liquid biopsy, and infectious disease detection.

The companies are applying Personalis' technology to explore immune response to genetic therapeutics in Sarepta's pipeline.

Alphazyme will manufacture three Codexis enzymes, including a new high-fidelity DNA polymerase, and gain comarketing rights to certain other Codexis enzymes.

These hybrid capture-based methods target gene transcripts of interest, which could shrink sequencing costs for some experiments by as much as 90 percent.

Seven Bridges will help build a computational infrastructure to harmonize data from Zero Childhood Cancer with datasets from other research projects.

The company, along with Softbank Investment Advisers, is offering a total of 11.5 million shares of its common stock at $84 per share.

The company plans to use the funds for general corporate purposes, including, together with cash on hand, to repay borrowings under its term loan facility. 

The GenomeWeb Index rose more than 9 percent in May, following an 18 percent climb in April, a marked contrast to its negative performance in February and March.

For the three months ended Dec. 31, 2019, the firm reported total revenues from continuing operations of $1.9 million compared to $1.7 million in Q4 2018.

Sema4 said it will provide SARS-CoV-2 viral and antibody testing to Connecticut residents including state employees and first responders.

The infectious disease testing firm has developed a sequencing-based coronavirus assay, which it plans to commercialize through its sister firm BioID Genomics. 

The investment bank gave shares of the Temple City, California-based genetic testing company a buy rating and a $20 price target.

The deal will join Tangen's GeneSpark point-of-care instrument with LabWare's portable disease surveillance kit for SARS-CoV-2.

The company said that a large portion of the offering's proceeds would be used to end criminal and civil investigations over its past billing practices.

Including the new round, the maker of software to support precision oncology care and drug discovery has landed nearly $100 million in equity investments to date. 

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.